During a recent GSK webinar, Professor Norbert Berend and Dr Gur Levy discussed the principles of asthma management and its applications, specifically addressing and challenging the use of maintenance and reliever therapy (MART). Additionally, they also highlighted recent updates on the budesonide/formoterol PRN regimen.
Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 20210114000000
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.
Significant advancements in the treatment of acute lymphocytic leukaemia (ALL) in children have improved their outcomes. However, ALL treatment and eradication remain a major challenge in adults. In a recent webinar, two specialists from the US discussed current ALL treatment strategies and goals of future regimens.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 20210108072306
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
At the recent Mylan (a Viatris company) webinar ‘Find the Missing Millions: Advanced Treatments for Hepatitis, ’panelists Prof Dr Rosmawati Mohamed, consultant gastroenterologist and hepatologist at University Malaya Medical Centre, and Prof Dr Henry Chan, director of the Chinese University of Hong Kong’s Center of Liver Health, discussed the current challenges in reducing the impact of chronic hepatitis B and C, as well as the evidence supporting new antivirals in treatment guidelines.
In an interview, Dr Eric Lee Kim Hor, a consultant paediatrician from Pantai Hospital Kuala Lumpur, spoke on the importance of vaccination in the prevention of influenza among children, resulting in the prevention of coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulting in coronavirus disease (COVID-19) as well as reduction of burden on the healthcare system.
At the Nimenrix Speaker Training Workshop webinar, Dr Amgad Gamil of Pfizer Inc. discussed updates on the epidemiology of invasive meningococcal disease (IMD), while simultaneously reviewing the latest immunogenicity and safety data of the MenACWY-TT vaccine (Nimenrix®, Pfizer) in the paediatric population.
The rising incidence of infections caused by multidrug-resistant (MDR) gram-negative bacteria has become a serious health threat and a major challenge for intensivists. Against a backdrop of high patient mortality and risk factors for infection in intensive care units (ICU), early adequate therapy is of paramount importance. At a recent Pfizer-sponsored symposium, Dr Asok Kurup, Infectious Disease Physician, Singapore presented the implications of MDR gram-negative infections in critically ill patients in Asia, while Dr Kenneth Chan, Respiratory Physician and Intensivist, Singapore highlighted the role of ceftazidime-avibactam (Zavicefta) and shared published real-world data on ceftazidime-avibactam.